AKBA Akebia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKBA

Price (delayed)

$0.979

Market cap

$262.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$148.87M

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 54

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is ...

Highlights
Akebia Therapeutics's EPS has soared by 64% YoY
AKBA's net income has soared by 55% YoY
AKBA's gross profit is up by 50% year-on-year but it is down by 4.3% since the previous quarter
The company's gross margin rose by 19% YoY but it fell by 2.8% QoQ
The company's quick ratio fell by 32% YoY and by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://akebia.com
Peers: JNJ NVS AMGN NKTR

Key stats

What are the main financial stats of AKBA

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
0.96%
1 week
-6.76%
1 month
-34.73%
1 year
-73.1%
YTD
-39.19%
QTD
-29.57%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$232.4M
Gross profit
$188.28M
Operating income
$8.69M
Net income
-$20.51M
Gross margin
81%
Net margin
-8.8%
The operating income has surged by 146% year-on-year but it has dropped by 68% since the previous quarter
The operating margin has soared by 136% YoY but it has plunged by 68% from the previous quarter
AKBA's net margin has surged by 64% year-on-year
AKBA's net income has soared by 55% YoY

Price vs fundamentals

How does AKBA's price correlate with its fundamentals

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
9.58
P/S
1.12
EV/EBIT
63.65
EV/EBITDA
60.84
EV/Sales
0.64
Akebia Therapeutics's EPS has soared by 64% YoY
AKBA's P/B is 51% below its last 4 quarters average of 19.2
The equity is down by 16% since the previous quarter but it is up by 11% year-on-year
The price to sales (P/S) is 60% less than the last 4 quarters average of 2.8 and 31% less than the 5-year quarterly average of 1.6
Akebia Therapeutics's revenue has increased by 26% YoY

Efficiency

How efficient is Akebia Therapeutics business performance
The return on invested capital has surged by 119% year-on-year but it has dropped by 83% since the previous quarter
Akebia Therapeutics's ROS has soared by 108% YoY but it has plunged by 89% from the previous quarter
The ROA has soared by 70% YoY

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 8% greater than its total liabilities
Akebia Therapeutics's current ratio has decreased by 37% YoY and by 10% QoQ
The company's quick ratio fell by 32% YoY and by 8% QoQ
AKBA's debt is 79% greater than its equity
The debt to equity has increased by 21% since the previous quarter but it has declined by 10% year-on-year
The equity is down by 16% since the previous quarter but it is up by 11% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.